Navigation Links
CryoCath Reports Data Presented at the 74th Annual Meeting of the German Cardiac Society
Date:4/3/2008

Toronto Stock Exchange Symbol: CYT

http://www.cryocath.com

MONTREAL, April 3 /PRNewswire-FirstCall/ - CryoCath (TSX: CYT), the global leader in cryotherapy products to treat cardiac arrhythmias, today announced that data on the Company's Arctic Front(R) catheter system to treat Atrial Fibrillation (AFib) was presented at the 74th Annual Meeting of the German Cardiac Society in Mannheim, Germany, March 27-29, 2008. CryoCath was well represented at the meeting, with a record number of presentations on cryo-ablation. In total there were eight poster presentations and ten oral presentations, including a standing room only cryo symposium from leading electrophysiologists that received 50 percent more attendance than the previous year.

Some of the highlights of the meeting include:

- Data from a three centre AFib study on Arctic Front by Professor Dr.

Schumacher from Herz- und GefaB-Klinik in Bad Neustadt, Germany,

Dr. Pitschner from the Kerckhoff-Klinik in Bad Nauheim, Germany and

Dr. Vogt from the Herz und Diabetes Zentrum NRW in Bad Oeynhausen,

Germany. With a median follow-up time of 12 months, 74 percent of the

293 paroxysmal patients enrolled were AFib free after only one

procedure and off anti-arrhythmic drugs (AADs).

- Dr. Heintze, also from the Herz und Diabetes Zentrum NRW, presented

follow up data on 168 patients treated in his center. This data

includes patients from the three center AFib study listed above as

well as a significant number of patients treated subsequently. The

group of AFib sufferers was largely paroxysmal with approximately

7 percent persistent. After an average of 8.5 months follow up,

81 percent were AFib free and off drugs and more than 85 percent were

considered a clinical success.

- Data from all presentations collectively determined that with proper

management of the procedure and medical monitoring, the safety

profile of Arctic Front continues to be very strong with no

significant, long-term complications or Major Adverse Cardiac Events

(MACE). Phrenic nerve palsies were largely transient and were

resolved by the end of the procedure or hospital discharge and the

remainder by the 12 month follow up visit.

"This data, in line with previously reported results, bolsters our confidence that Arctic Front is rapidly becoming the standard of care for paroxysmal AFib," said Jan Keltjens, President and CEO of CryoCath. "What is exciting is the consistency these results represent. They are in line with results from our STOP AF IDE feasibility studies and data presented at previous scientific conferences and symposiums. It means Arctic Front is doing what it's supposed to do - provide a simple, anatomical based procedure resulting in safe and consistently efficacious outcomes."

About Arctic Front

Arctic Front is a minimally invasive cryo-balloon catheter designed specifically to treat paroxysmal Atrial Fibrillation. This bi-directional, double balloon catheter enables physicians to rapidly isolate all four pulmonary veins for the treatment of AFib. As of the end of December 2007, an estimated 2100 patients have been treated in 34 centers across Europe since approval.

About CryoCath

CryoCath - http://www.cryocath.com - is a medical technology company that leads the world in cryotherapy products to treat cardiac arrhythmias. With a priority focus on providing physicians with a complete solution of catheter products to treat cardiac arrhythmias, CryoCath has multiple products approved in the U.S., across Europe and several ROW countries. The Company is developing additional products to expand its pipeline of products to treat cardiac arrhythmias.

This press release includes "forward-looking statements" that are subject to risks and uncertainties, including with respect to the timing of regulatory trials and their outcome. For information identifying legislative or regulatory, economic, climatic, currency, technological, competitive and other important factors that could cause actual results to differ materially from those anticipated in the forward looking statements, see CryoCath's annual report available at http://www.sedar.com under the heading Risks and Uncertainties in the Management's Discussion and Analysis section.


'/>"/>
SOURCE CryoCath Technologies Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. CryoCath files patent infringement lawsuit
2. CryoCath to present at CIBC Healthcare Conference
3. CryoCath to present at Piper Jaffray and BMO Healthcare conferences
4. CryoCath announces 2007 fourth quarter and fiscal year end financial results
5. CryoCath intends to contest patent infringement claim by CryoCor, Inc.
6. CryoCath to Hold First Quarter 2008 Conference Call and Webcast
7. CryoCath Provides Update on Patent Infringement Lawsuit
8. CryoCath Announces Fiscal 2008 First Quarter Results
9. CryoCath Technologies notice of annual meeting
10. CryoCath Appoints New Chief Financial Officer
11. CryoCath Introduces Arctic Front in Australia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... ... ... CloudLIMS, joins an elite number of companies that have earned a spot on ... CIOReview. , In a deliberate session with the honorary industrial experts, a list of ... with. The positioning is based on evaluation of CloudLIMS’ specialties in Automated Sample Management ...
(Date:5/25/2016)... ... 25, 2016 , ... DKT International, one of the largest ... pleased to release their 2015 global impact data. In 2015, DKT served over ... deaths and 3.8 million unsafe abortions across 21 countries worldwide. , “We ...
(Date:5/25/2016)... Mexico (PRWEB) , ... May 25, 2016 , ... Casa ... the restorative properties of precious stones to complement its new wellness suites . ... two floors and feature a plethora of special services and insuite amenities, from a ...
(Date:5/25/2016)... ... ... more than fifty years, we've suffered whiplash as each new scientific study seemed to contradict ... nutritional advice – advice that was supposed to keep us healthy and slim. And what ... are considered to be overweight and more than 1 in 3 adults are considered to ...
(Date:5/25/2016)... ... 25, 2016 , ... Researchers from SUNY State College of Optometry won the ... visual evoked potential and human attention. The article, VEP and Human Attention: Translation ... ERG and VEP Vision Testing System (Diopsys, Inc., Pine Brook, NJ) to record ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)...   , Study met both ... in , Excellent plus Good ... of the ascending colon   ,      ... announced new positive data from the phase III MORA study for ... litre PEG with ascorbate. The study met both primary endpoints showing ...
(Date:5/24/2016)... 2016 ARANZ Medical  Ltd a ... sector, has been named the Coretex Hi-Tech Emerging Company of ... Dr Bruce Davey , CEO of ARANZ Medical ... really good to be recognised for the work we are ... used in 35 countries around the world from Sub-Saharan Africa ...
(Date:5/24/2016)... 2016 Celsion Corporation (NASDAQ: ... provided an update on its ongoing OVATION study, ... GEN-1, the Company,s DNA-based immunotherapy, with the standard ... with advanced ovarian cancer who will undergo neoadjuvant ... an IL-12 DNA plasmid vector formulated as a ...
Breaking Medicine Technology: